Treatment of collecting duct carcinoma: current status and future perspectives.

摘要: BACKGROUND Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting. The present study evaluated activity of targeted therapies metastatic CDC. PATIENTS AND METHODS We a cohort 384 consecutive patients with renal cell (mRCC). characteristics CDC were compared against those remaining cohort. All treated therapies. RESULTS Thirteen referred to our Center (incidence: 3.4% all mRCC). Median age was 57 and 62 years non-CDC groups, respectively. overall disease control population 23%, median survival 4 (95% confidence interval(CI)=2.4-5.6) months. Three obtained satisfying response (disease lasting 6-33 months). CONCLUSION poor prognosis carcinoma. Treatment represents future challenge may play role selected cases.